Clinical trials for medicines: guidance on quality and risk proportionality

AI Summary

This guidance outlines the UK Medicines and Healthcare products Regulatory Agency (MHRA) expectations following the full implementation of the amended Clinical Trials Regulations in April 2026. The regulatory framework adopts international standards from ICH E6 (R3) and ICH E8 (R1), mandating that all UK clinical trials for investigational medicinal products move away from rigid, 'one-size-fits-all' quality models. Instead, organizations must adopt a risk-proportionate approach focused on 'Quality by Design' (QbD) and 'Risk-Based Quality Management' (RBQM). Main requirements include the early identification of 'Critical to Quality' (CTQ) factors—attributes essential to participant safety and the reliability of trial results. Sponsors are required to establish a dynamic risk management framework that utilizes Key Risk Indicators (KRIs) and Quality Tolerance Limits (QTLs) to proactively detect and escalate issues. The guidance highlights that common failures often stem from a lack of cross-functional engagement or prioritizing financial milestones over scientific rigor. Required actions for sponsors and investigators include documenting all risk-mitigation strategies within the Trial Master File (TMF) and ensuring that quality planning is integrated into the protocol before finalization. The MHRA will assess these frameworks during inspections, specifically looking for evidence of continuous risk review, stakeholder communication, and the effectiveness of implemented controls. While the guidance applies to all companies conducting UK clinical trials, it emphasizes that regulatory compliance depends on a coherent narrative that links risk management activities directly to participant protection and data integrity.